| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| bevacizumab + erlotinib | epidermal growth factor receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Liver carcinoma[MeSHID:D006528] Colorectal Cancer[MeSHID:D015179] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Squamous cell carcinoma[MeSHID:D002294] |
NA | phase 3 | unknown |
| bevacizumab + erlotinib | vascular endothelial growth factor a | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Liver carcinoma[MeSHID:D006528] Colorectal Cancer[MeSHID:D015179] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Squamous cell carcinoma[MeSHID:D002294] |
NA | phase 3 | unknown |
| click here to return to the previous page | ||||||||